Breaking News

CPR Pharma Expands APAC Capabilities

March 26, 2013

Adds bioanalytical assay services

CPR Pharma Services has expanded it services in the Asia-Pacific region with a new lab in Adelaide, Australia that offers ligand binding assay services for biomarkers, monoclonal antibodies, biosimilars and biologics for early and late phase development. 
 
The new large molecule immunochemistry analytical service will be run by John Chappell, an expert in ligand binding assay development, validation and implementation. Mr. Chappell is a member of the AAPS Committee and has more than 20 years of CRO experience having held positions with Covance, ClinTrials BioResearch, BAS Analytics, Veeda and ICON. 
 
CPR’s chief executive officer, Jason Valentine, said, “John’s appointment with CPR will bring unparalleled expertise in biologic and biosimilar assay development and validation to the Asia/Pacific region. Monoclonal antibodies, proteins, biologics and biosimilars are the new growth areas in drug development and will progressively occupy a larger share of drugs developed globally. Couple this with the increased emphasis on biomarker monitoring in clinical trials and large molecule quantification is critical to any modern bioanalysis laboratory.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.